Microbot Medical is a pre-commercial stage medical device company developing robotic systems for endovascular procedures — minimally invasive surgeries performed by navigating guidewires and catheters through blood vessels to treat conditions like peripheral vascular disease, stroke, and coronary artery disease. Microbot's flagship product is the LIBERTY Endovascular Robotic Surgical System, which received FDA 510(k) clearance in September 2025 and launched in a limited U.S. market release in November 2025, with a full commercial launch planned for April 2026. LIBERTY is designed to remotely maneuver guidewires and catheters, keeping physicians out of the radiation field during procedures. Unlike most competing systems, LIBERTY is fully disposable and single-use, meaning hospitals do not need to purchase expensive capital equipment or dedicate a specialized lab. This disposable model is central to Microbot's differentiation. Microbot sells LIBERTY directly to hospitals and interventional radiology centers in the U.S., and plans to use distributors and partnerships internationally, with CE Mark approval in Europe anticipated in the second half of 2026. Revenue will be driven by hospital adoption, procedure volumes, and per-unit pricing. Microbot does not manufacture LIBERTY itself — production is outsourced to a single third-party subcontractor. Microbot pays royalties on net sales to the Technion and the Israeli Innovation Authority, which co-own or have funded the underlying IP. Microbot has 43 employees, with R&D and engineering based in Israel.